APM vs. MRKR, EYEN, VSTM, CLSD, PRPH, LFVN, ETON, TLSA, PMVP, and RLMD
Should you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Marker Therapeutics (MRKR), Eyenovia (EYEN), Verastem (VSTM), Clearside Biomedical (CLSD), ProPhase Labs (PRPH), LifeVantage (LFVN), Eton Pharmaceuticals (ETON), Tiziana Life Sciences (TLSA), PMV Pharmaceuticals (PMVP), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Aptorum Group (NASDAQ:APM) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
Aptorum Group has a net margin of 0.00% compared to Marker Therapeutics' net margin of -142.62%. Aptorum Group's return on equity of 0.00% beat Marker Therapeutics' return on equity.
Marker Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 184.24%. Given Marker Therapeutics' higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Aptorum Group.
Aptorum Group has higher earnings, but lower revenue than Marker Therapeutics.
In the previous week, Aptorum Group had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Aptorum Group and 1 mentions for Marker Therapeutics. Aptorum Group's average media sentiment score of 1.43 beat Marker Therapeutics' score of 0.73 indicating that Aptorum Group is being referred to more favorably in the media.
3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by insiders. Comparatively, 17.4% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Marker Therapeutics received 30 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 63.39% of users gave Marker Therapeutics an outperform vote.
Aptorum Group has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Summary
Aptorum Group beats Marker Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Aptorum Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptorum Group Competitors List
Related Companies and Tools
